

EQA round: TM3/23 - Tumour Markers

Deadline: 25.7.2023

Setup: groups - measurement principle, manufacturer of kit; Slovakia; minimal size of the groups n = 5

RoM = robust average	AV = assigned value	D _{max} = acceptable difference
SD = standard deviation	CVPG = consensus of the participants' groups	LL = lower limit
CV = coefficient of variation	U _{AV} = expanded uncertainty of the assigned value (k = 2)	UL = upper limit
N _{tot} = total number of the results		N _{eva} = number of the results assessed
N _{out} = number of the results removed before calculation		N _{suc} = number of successful results
		S _{rel} = relative success

Test Sample Group	[unit]	RoM	SD	CV [%]	N _{tot}	N _{out}	Comparability					N _{eva}	N _{suc}	S _{rel} [%]
							AV	U _{AV}	D _{max}	LL	UL			
(208) β-2-microglobulin	[mg/L]				7							7	7	100
Sample A												7	7	100
Other					7	0	1x 6/1, 2x 6/58, 2x 6/60, 1x 6/91, 1x 6/179					7		
Sample B												7	7	100
Other					7	0	1x 6/1, 2x 6/58, 2x 6/60, 1x 6/91, 1x 6/179					7		
(185) AFP	[µg/L]				8							8	8	100
Sample A												8	8	100
Other					8	0	2x 4/1, 2x 4/12, 3x 4/60, 1x 4/179					8		
Sample B												8	8	100
Other					8	0	2x 4/1, 2x 4/12, 3x 4/60, 1x 4/179					8		
(181) CA 15-3	[kU/L]				7							7	7	100
Sample A												7	7	100
Other					7	0	2x 4/1, 1x 4/12, 4x 4/60					7		
Sample B												7	7	100
Other					7	0	2x 4/1, 1x 4/12, 4x 4/60					7		
(182) CA 19-9	[kU/L]				8							8	6	75
Sample A												8	6	75
Other					8	0	2x 4/1, 2x 4/12, 3x 4/60, 1x 4/179					8		
Sample B												8	7	88
Other					8	0	2x 4/1, 2x 4/12, 3x 4/60, 1x 4/179					8		
(183) CA 72-4	[kU/L]				7							7	7	100
Sample A												7	7	100
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		1,35	0,13	9,4	7	0	CVPG	1,43	0,024	22%	1,11	1,75	7	
Sample B												7	7	100
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		1,93	0,19	9,6	7	0	CVPG	2,04	0,037	22%	1,59	2,49	7	
(180) CA 125	[kU/L]				8							8	8	100
Sample A												8	8	100
Other					8	0	3x 4/1, 1x 4/12, 3x 4/60, 1x 4/179					8		
Sample B												8	8	100
Other					8	0	3x 4/1, 1x 4/12, 3x 4/60, 1x 4/179					8		
(189) CEA	[µg/L]				8							8	8	100
Sample A												8	8	100
Other					8	0	2x 4/1, 2x 4/12, 3x 4/60, 1x 4/179					8		
Sample B												8	8	100
Other					8	0	2x 4/1, 2x 4/12, 3x 4/60, 1x 4/179					8		
(184) CYFRA 21-1	[µg/L]				8							8	8	100
Sample A												8	8	100
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		2,53	0,14	5,6	8							8	8	100
Other		2,53	0,13	5,3	7	0	CVPG	2,48	0,031	18%	2,03	2,93	7	
					1	0	1x 4/1					1		
Sample B												8	8	100
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		2,9	0,25	8,7	8							8	8	100
Other		2,93	0,21	7,1	7	0	CVPG	2,89	0,032	18%	2,36	3,42	7	
					1	0	1x 4/1					1		
(186) hCG	[U/L]				9							7	7	100
Sample A												7	7	100
Other					9	0	3x 4/12, 3x 4/60, 1x 4/179, 2x 4/210					7		
Sample B												7	7	100
Other					9	0	3x 4/12, 3x 4/60, 1x 4/179, 2x 4/210					7		

EQA round: TM3/23 - Tumour Markers

Deadline: 25.7.2023

Setup: groups - measurement principle, manufacturer of kit; Slovakia; minimal size of the groups n = 5

Test Sample Group	[unit]	RoM	SD	CV [%]	N _{tot}	N _{out}	Comparability					N _{eva}	N _{suc}	S _{rel} [%]
							AV	U _{AV}	D _{max}	LL	UL			
(206) Calcitonin	[ng/L]				1							1	1	100
Sample A												1	1	100
Other					1	0						1		
														1x 4/60
Sample B												1	1	100
Other					1	0						1		
														1x 4/60
(194) NSE	[µg/L]				8							8	8	100
Sample A												8	8	100
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		49,6	6,2	13	8	0	CVPG	52	0,5	30%	36,4	67,6	8	
Sample B												8	8	100
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		18,6	2,2	12	8	0	CVPG	19,5	0,23	30%	13,6	25,4	8	
(191) PSA	[µg/L]				7							6	6	100
Sample A												6	6	100
Other					7	0						6		
														1x 4/1, 1x 4/12, 3x 4/60, 1x 4/179, 1x 4/195
Sample B												6	6	100
Other					7	0						6		
														1x 4/1, 1x 4/12, 3x 4/60, 1x 4/179, 1x 4/195
(198) free-PSA	[µg/L]				5							4	4	100
Sample A												4	4	100
Other					5	0						4		
														1x 4/1, 2x 4/60, 1x 4/179, 1x 4/195
Sample B												4	4	100
Other					5	0						4		
														1x 4/1, 2x 4/60, 1x 4/179, 1x 4/195
(201) S-100	[µg/L]				4							4	4	100
Sample A												4	4	100
Other					4	0						4		
														4x 4/60
Sample B												4	4	100
Other					4	0						4		
														4x 4/60
(195) SCCA	[µg/L]				5							5	5	100
Sample A												5	5	100
Other					5	0						5		
														3x 4/1, 2x 4/60
Sample B												5	5	100
Other					5	0						5		
														3x 4/1, 2x 4/60
(207) Thyreoglobulin	[µg/L]				3							3	3	100
Sample A												3	3	100
Other					3	0						3		
														1x 4/12, 2x 4/60
Sample B												3	3	100
Other					3	0						3		
														1x 4/12, 2x 4/60